Honest, research-backed journalism on ivermectin, fenbendazole, HCQ, and your right to medical sovereignty. Updated daily.
Azithromycin lingers in tissues long after blood levels fall, thanks to cellular trapping and immune-cell transport. Here's the real pharmacology behind it.
Streptococcus pneumoniae has developed real, well-documented resistance to azithromycin and related macrolides. Here is what the evidence shows about how and why.
Azithromycin carries a recognized but small risk of heart rhythm changes. Here is what the actual research shows, and who should discuss it with a physician.
Azithromycin's interactions differ by formulation and by drug. Here is what the actual pharmacokinetic and outcomes research shows.
Azithromycin, clarithromycin, and erythromycin share one ribosomal target but differ sharply in chemistry, dosing, and safety.
Azithromycin remains useful for community-acquired pneumonia, but rising resistance has narrowed its role. Here's what current guidelines and evidence show.
Azithromycin's unusual chemical design gives it real staying power on the shelf. Here is what the evidence shows about storage, expiration, and stability.
A clear look at when azithromycin (the Z-Pack) actually helps respiratory infections, what the trial evidence shows, and standard dosing.
Azithromycin stops bacteria from building proteins by jamming their ribosomes. Here's the molecular story behind the Z-Pack, and what it does and doesn't treat.